ELVN
insider transactionsEnliven Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-523.6K
0 buy · 523.6K sell
Net value · 365d
-$19.2M
$0 in · $19.2M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
21
0 buy · 523.6K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
$12.3M
272.3K sh · $45.02
Own -4%
-
Sell·S
$409.1K
9.1K sh · $45.02
Own -4%
-
Sell·S
Director · 10b5-1
$12.7K
354 sh · $35.82
Own -1%
-
Sell·S
Director · 10b5-1
$66.0K
1.9K sh · $35.36
Own -3%
-
Sell·S
Director · 10b5-1
$266.7K
7.8K sh · $34.28
Own -13%
-
Sell·S
Benjamin Hohl KEY
CHIEF FINANCIAL OFFICER
$295.8K
10.0K sh · $29.58
Own -16%
-
Sell·S
Director · 10b5-1
$32.2K
1.2K sh · $26.18
Own -5%
-
Grant·A
CHIEF OPERATING OFFICER
$0
120.0K sh
Own New
-
Grant·A
CHIEF OPERATING OFFICER
$0
20.0K sh
Own New
-
Grant·A
CHIEF SCIENTIFIC OFFICER
$0
112.5K sh
Own New
-
Grant·A
CHIEF SCIENTIFIC OFFICER
$0
18.8K sh
Own New
-
Grant·A
Benjamin Hohl KEY
CHIEF FINANCIAL OFFICER
$0
150.0K sh
Own New
-
Grant·A
Benjamin Hohl KEY
CHIEF FINANCIAL OFFICER
$0
25.0K sh
Own +69%
-
Grant·A
Director
$0
19.2K sh
Own New
-
Grant·A
Director
$0
1.6K sh
Own New
-
Grant·A
Director
$0
34.0K sh
Own New
-
Grant·A
Director
$0
17.1K sh
Own New
-
Grant·A
Director
$0
1.4K sh
Own New
-
Grant·A
Director
$0
17.1K sh
Own New
-
Grant·A
Director
$0
17.1K sh
Own New
-
Sell·S
CHIEF SCIENTIFIC OFFICER · 10b5-1
$145.2K
5.0K sh · $29.04
Own -1%
-
Sell·S
CHIEF SCIENTIFIC OFFICER · 10b5-1
$390.3K
14.5K sh · $26.90
Own -2%
-
Sell·S
CHIEF SCIENTIFIC OFFICER · 10b5-1
$144.8K
5.5K sh · $26.37
Own -1%
-
Sell·S
Director · 10b5-1
$19.4K
718 sh · $26.96
Own -3%
-
Sell·S
Director · 10b5-1
$13.5K
512 sh · $26.46
Own -2%
-
Sell·S
CHIEF SCIENTIFIC OFFICER · 10b5-1
$1.5M
50.0K sh · $29.13
Own -6%
-
Sell·S
CHIEF SCIENTIFIC OFFICER · 10b5-1
$1.0M
41.2K sh · $24.90
Own -5%
-
Sell·S
Director · 10b5-1
$107.1K
4.3K sh · $25.00
Own -15%
-
Sell·S
CHIEF OPERATING OFFICER · 10b5-1
$6.9K
243 sh · $28.50
Own -0%
-
Sell·S
CHIEF OPERATING OFFICER · 10b5-1
$1.3M
48.1K sh · $27.98
Own -18%
-
Sell·S
CHIEF SCIENTIFIC OFFICER · 10b5-1
$842.5K
33.8K sh · $24.92
Own -4%
-
Sell·S
CHIEF SCIENTIFIC OFFICER · 10b5-1
$151.0K
7.5K sh · $20.13
Own -1%
-
Sell·S
Director · 10b5-1
$200.7K
8.0K sh · $25.04
Own -21%
-
Sell·S
Director · 10b5-1
$40.5K
1.6K sh · $25.00
Own -6%
-
Grant·A
Director
$0
59.4K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | ORBIMED ADVISORS LLC / OrbiMed Capital GP VII LLC / OrbiMed Genesis GP LLC | Sell S | 272.3K | $12.3M |
| Jun 15, 2026 | ORBIMED ADVISORS LLC / OrbiMed Capital GP VII LLC / OrbiMed Genesis GP LLC | Sell S | 9.1K | $409.1K |
| Jun 5, 2026 | Lori Anne Kunkel 10b5-1 | Sell S | 354 | $12.7K |
| Jun 5, 2026 | Lori Anne Kunkel 10b5-1 | Sell S | 1.9K | $66.0K |
| Jun 5, 2026 | Lori Anne Kunkel 10b5-1 | Sell S | 7.8K | $266.7K |
| Mar 6, 2026 | Benjamin Hohl KEY | Sell S | 10.0K | $295.8K |
| Feb 17, 2026 | Richard A. Heyman 10b5-1 | Sell S | 1.2K | $32.2K |
| Feb 12, 2026 | Anish Patel | Grant A | 120.0K | $0 |
| Feb 12, 2026 | Anish Patel | Grant A | 20.0K | $0 |
| Feb 12, 2026 | Joseph P Lyssikatos | Grant A | 112.5K | $0 |
| Feb 12, 2026 | Joseph P Lyssikatos | Grant A | 18.8K | $0 |
| Feb 12, 2026 | Benjamin Hohl KEY | Grant A | 150.0K | $0 |
| Feb 12, 2026 | Benjamin Hohl KEY | Grant A | 25.0K | $0 |
| Feb 12, 2026 | Richard A. Heyman | Grant A | 19.2K | $0 |
| Feb 12, 2026 | Rishi Gupta | Grant A | 1.6K | $0 |
| Feb 12, 2026 | Rishi Gupta | Grant A | 34.0K | $0 |
| Feb 12, 2026 | Lori Anne Kunkel | Grant A | 17.1K | $0 |
| Feb 12, 2026 | Scott J. Garland | Grant A | 1.4K | $0 |
| Feb 12, 2026 | Mika K Derynck | Grant A | 17.1K | $0 |
| Feb 12, 2026 | Rahul D. Ballal | Grant A | 17.1K | $0 |
| Feb 6, 2026 | Joseph P Lyssikatos 10b5-1 | Sell S | 5.0K | $145.2K |
| Jan 20, 2026 | Joseph P Lyssikatos 10b5-1 | Sell S | 14.5K | $390.3K |
| Jan 20, 2026 | Joseph P Lyssikatos 10b5-1 | Sell S | 5.5K | $144.8K |
| Jan 20, 2026 | Richard A. Heyman 10b5-1 | Sell S | 718 | $19.4K |
| Jan 20, 2026 | Richard A. Heyman 10b5-1 | Sell S | 512 | $13.5K |
| Jan 9, 2026 | Joseph P Lyssikatos 10b5-1 | Sell S | 50.0K | $1.5M |
| Jan 9, 2026 | Joseph P Lyssikatos 10b5-1 | Sell S | 41.2K | $1.0M |
| Jan 9, 2026 | Richard A. Heyman 10b5-1 | Sell S | 4.3K | $107.1K |
| Jan 9, 2026 | Anish Patel 10b5-1 | Sell S | 243 | $6.9K |
| Jan 9, 2026 | Anish Patel 10b5-1 | Sell S | 48.1K | $1.3M |
| Jan 8, 2026 | Joseph P Lyssikatos 10b5-1 | Sell S | 33.8K | $842.5K |
| Jan 8, 2026 | Joseph P Lyssikatos 10b5-1 | Sell S | 7.5K | $151.0K |
| Jan 8, 2026 | Richard A. Heyman 10b5-1 | Sell S | 8.0K | $200.7K |
| Jan 8, 2026 | Richard A. Heyman 10b5-1 | Sell S | 1.6K | $40.5K |
| Jan 7, 2026 | Scott J. Garland | Grant A | 59.4K | $0 |
About ELVN insider trading
This page tracks insider transactions for Enliven Therapeutics, Inc. (ELVN) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.